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ABSTRACT
Superoxide dismutase (SOD) is the scavenger of superoxide anion (Oz) and functions as a protector of
living bodies. Study of a model compound of SOD is important when searching for the relationship between
functions and structures of enzymes. Furthermore, SOD model compounds have potential for therapeutic
usefulness. Although many SOD model compounds have been reported, their structures are quite different
from those of the native enzyme. Cu,Zn-SOD has been proposed for clinical uses. Unfortunately, many
problems such as half-lifetime and antigenicity have not been overcome even though several copper(II)
complexes are known to show SOD activity. Active oxygen species such as superoxide (Oz’), being formed
by leakage of electrons to oxygen (Oz) from various components of the cellular electron transport chains, and
provided during the respiratory burst of phagocytic cells, have been implicated both in the aging process and
in degenerative diseases, including arthritis and cancer. Therefore, the biological system posseses the
protective mechanisms against active species.
Abbreviations: Cu,Zn-SOD; copper, zinc-containing superoxide dismutase; SOD, superoxide dismutase;
Mn-SOD; manganese-containing superoxide dismutase; Fe-SOD, iron-containing superoxide dismutase.
INTRODUCTION
The reactive superoxide radical anion, Oz, is a product of the oxygen metabolic cycle/1/. The radical
anion is a highly reactive toxic species in many biological systems. Superoxide dismutase (SOD) catalyses
Oz dismutation very efficiently and it serves as an important means of defense against oxygen toxicity. It has
been discovered /2/ that the superoxide dismutase enzymes catalyze disproportionation of the toxic
superoxide ions into molecular oxygen and HzOz (Eq. 1).
2Oz + 2H + SOD Oz + HzO_ ()
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The in vivo ubiquity of the SODs makes them very efficient in normal conditions. However, in the case of
an oxygen burst (during reperfusion following ischemia, for instance) the natural defenses of the organism
are insufficient, leading to lipid peroxidation, membrane damage, and cell death. These effects are not
directly due to the superoxide anion, but rather to the more potent oxidant, the hydroxyl radicals, which is
generated in situ. In order to make up for the SOD deficiency, the first idea was to introduce supplementary
SODs into the organism. However, SODs have molecular weights too high to cross cell membranes/3/and
can only provide extracellular protection/4/. In order to circumvent this difficulty, low-molecular mass
synthetic compounds that mimic SODs have been investigated/5/. As copper has been proven to be the
active metal center in the best studied SOD (Cu,Zn-SOD), many cuprous complexes have been synthesized
and tested for SOD-like activity/3, 5, 6/and most them appeared to be very efficient. The problem is that
they lose their activity in vivo/3, 7/. Proteins appear to have better affinities for copper than the studied
ligands, so Cu is inactivated once it is embedded in the proteins. The other two classes of SODs, which
contain iron or manganese, have received less attention, and their structures have only recently been
described/3, 8/. However, some Fe/7, 9, 10/and Mn/7, 9, 11/SOD mimics have been reported, and some of
them show a marked SOD activity and seem to keep it in living cells/10, 11/.
From all these results on native SODs or low molecular weight SOD mimics, it seems that the presence
of coordination sites belonging to nitrogen heteroaromatic rings such as imidazoles or pyridines is important
to have high SOD activity that is not affected by biological chelators/3, 10/. The problem to solve when
searching for SOD-like complexes is to find a balance between a sufficient stability necessary to survive in
vivo conditions and a certain flexibility that allows the change of metal coordination occuring during the
catalytic process. Apart from the use of various metalloporphyrins/3/, only a few mono- /12/ and bitopie (13)
macrocyclic Cu (II) complexes have been investigated as potential SOD-like derivatives, but as aeyelie Cu
(II) complexes, they do not resist biological chelators. Recently, two Mn (II) macrocyclic complexes have
been shown to exhibit catalytic SOD activity maintained in vivo conditions (13). Many research groups have
been pursuing the possibility of developing such "synzymes" (synthetic enzymes) as an approach to
managing various types of diseases. Tremendous progress has been made in this area in recent years, both in
defining a role for such a synthetic enzyme as a human pharmacological agent by utilizing a number of
animal models for disease, and in progressing toward development of actual drug candidates. The following
review briefly introduces the chemistry of the SOD enzymes, surveys recent advances in the synthesis of low
molecular weight SOD mimics, and attempts to introduce some of the issues involved with the testing for
SOD activity and the chemical design constraints one must satisfy in order to synthesize a highly active
enzyme mimic which can function as a human pharmaceutical agent. In particular, emphasis will be made in
this review on considerations of development of functional models for a SOD for the metal complexes
reported to possess SOD synzyme activity and recent developments in the chemistry ofSOD which may have
implications for these areas.
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MECHANISTIC ASPECTS
The major function of superoxide dismutase (SOD) is to catalyze the dismutation of superoxide anions
(02) and to control intracellular and extracellular concentrations of 02"/14/. 02" is the mediator of many
diseases. It is involved in radiation injury, DNA damage, lipid peroxidation and vascular diseases/15, 16/.
Although SOD has been considered for application as a pharmaceutical for many years/17/, some problems
have been encountered in clinical trials, because SOD has some disadvantages such as high cost, instability,
cell impermeability and immunogenicity. Therefore, the stable, non-toxic, low molecular weight metal
complexes (model compounds) which catalyze the dismutation of 02 have attracted much attention/18-23/.
It is of great importance to study the structures, thermodynamic and kinetic properties of SOD model
compounds and their mechanism of catalytic dismutation of 02 when searching for relationships of
structures, properties and functions and medical uses of metal complexes/24, 25/. Until now several Cu (If)
complexes for mimicking Cu2Zn2SOD have been described, such as Cu (II) complexes of polypeptides/26,
27/, polydentate Schiff bases/16, 28/, mixed ligand/12, 29/, imidazolate-bridged heterobinuclear Cu-Zn
complexes/30, 31/, and complexes of macrocyclic ligands/31, 5/. Some of them were shown to mimic the
structures ofCu2Zn2SOD to different extents, and others can mimic their functions.
Reactive oxygen species such as superoxide anion, hydroxyl radical, hydrogen peroxide, and single
oxygen have been postulated as playing an important role in a wide variety of pathological processes/32/.
Cu,Zn-superoxide dismutase (SOD), which controls reactive oxygen species via disproportionation of 02"
radicals into 02 and H202, has been proposed for clinical uses/33, 34/. Unfortunately, intravenously injected
SOD disappears from the circulation with a half-life of the order of some minutes/35/. Most SOD research
has been directed at prolonging the half-life and, of course, maintaining full enzymatic activity/36/. Even if
substantial advances have been made in the development of SOD derivatives that enhance lifetimes/37, 38/,
the limiting factor in the use of such compounds, antigenicity, has not been overcome/39/. A variety of low
molecular weight SOD mimics have been prepared, both as antioxidants and pharmaceutical agents.
Manganese/17/, iron/40/, or copper ions/5/either free or complexed, are known as efficient catalysts of the
dismutation process. A variety of copper complexes of 1, 10-phenanthroline, amino acids, peptides,
salicylates, macrocycles, and Schiff base derivatives have been verified as catalysts for superoxide
dismutation/41, 12/. Even if SOD mimics, based on complexed copper, can be stoichiometric rather than
catalytic scavengers of oxygen radicals, copper, once freed from the complexity agent, might catalyze
hydroxyl radical formation. Furthermore, some potent effects of copper (II) compounds with antioxidant
activity have been registered/42, 43/. Recently, kinetic and thermodynamic considerations have shown that
Cu, Zn-superoxide dismutase is unique in its ability to catalyze 02 dismutation in vivo in contrast to copper
compounds which have this feature in vitro, due to different reactivity towards dioxygen (low for SOD and
high for copper complexes)/44/. If, by means of this contribution, it is suggested that copper compounds may
efficiently replace SOD only in those pathological processes in which the local concentration of 02" can be
rather high, it is not clear which parameters are involved in the differing dismutation ability shown by
different copper complexes in vitro. Although some hypotheses have been put forward/45, 46/, there is some
doubt that the proposed activity-structure relationships are correct. In fact, not considering that copper forms
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dissolved in the reaction medium. In a medium where competitive ligands such as buffer, xanthine, and OH"
are present; this type and concentration of copper compounds can change, invalidating any structure-activity
correlation. Recently, Costanzo et al. have found that some copper complexes have a productive effect
against photohemolysis sensitized by 2-(3-benzoylphenyl) propionic acid (ketoprofen)/15/, a drug which
undergoes photodegradation involving a superoxide radical as a reactive intermediate /47/. Site-directed
mutagenesis is an important tool in studying and understanding the factors determining enzymatic
mechanisms and the role of the residues involved in the catalytic reaction/48, 49/. Substitution of some of
the potentially critical residues in the active site cavity of CuzZn2 superoxide dismutase (SOD hereafter) has
recently led to a better understanding of their role in the catalytic mechanism/50, 51/.
SODs are, in the majority of cases, cytoplasmic enzymes, predominantly found in eukaryotes, which
protect cells against the toxicity of superoxide, a by product of aerobic metabolism. SOD is a very efficient
catalyst for the dismutation of superoxide to molecular oxygen and hydrogen peroxide/2, 52/. Moreover
SOD is a dimer of identical subunits, each of them containing one copper and one zinc ion/53/, the copper
ion being essential for the catalytic reaction. The. efficient catalytic properties of SOD depend on the redox
potential of the Cu+Z/Cu+ pair, which is intermediate between the potentials of the pairs O2/02 and Oz/O2"2.
During the catalytic reaction, the copper ion is cyclically reduced and oxidized with the consequent
production of O2 and H202 respectively/54/. Both reactions have rate constants of about 2 x 109 S
"1 M"1/55/;
such high rates are thought to be due to increased substrate attraction towards the active channel due to
positive electrostatic field at its entrance/55/.
CuZn-SUPEROXIDE DISMUTASE
CuZn-SOD is a metalloprotein which catalyzes the scavenging of superoxide anion 02" (Eq. 2)/56/.
202" + 2H
/ + Cu-SOD H20 + 0 + Cu-SOD (2)
The catalytic site is composed of a copper (II) ion ligated by four histidines and water molecule in a
distorted five-coordinated geometry and a Zn (II) ion ligaTed by three histidines and an aspartate in a
distorted tetrahedral environment/57/. Only the copper (II) ion undergoes oxidation-reduction cycling during
the dismutation of O2/58/. The zinc ions are not involved in the redox cycle, but maintain ,the configuration
of the active site and facilitate the oxidation step/59, 60/. In recent years particular attention has been paid to
synthetic analogs of Cu, Zn-SOD /61, 62/. In this perspective, the coordination structures and redox
potentials of each Cu (II) ion in the synthesized copper (II) complexes which can be considered to possess
SOD-mimic activity were found to play a significant role/57/. Copper-zinc-superoxide dismutase (Cu-Zn-
SOD) is believed to protect cells from the toxic effect of superoxide ion by catalyzing the dismutation
reaction of O2/2, 11/. X-ray crystal structure analysis shows that the active site of Cu, Zn-SOD from bovine
erythrocytes comprises two identical subunits, each of which contains a histidine (imidazolate)-bridged Cu
(II)-Zn (II) active center. In Cu-Zn-SOD/63/, the subunits contain fully active imidazolate-bridged bimetallic
centers in which Cu (II) has replaced Zn (If).
Numerous imidazolate-bridged binuclear copper (II) complexes have been prepared and characterized as
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models for Cu, Zn-SOD active site. Two imidazolate-bridged mononuclear complexes proved to be
insufficient as models because their imidazolate bridge in aqueous solution is stable only in a very narrow pH
range. In order to obtain imidazolate-bridged binuclear copper (II) complexes that are stable over a larger pH
range, several imidazolate-bridged dicopper (II) complexes with macrocyclic ligands have been reported/64,
65/and been considered to be better Cu, Zn-SOD (or Cu, Cu-SOD) mimics due to their enhanced stability by
the presence of the binucleating macrocycles or macrobicycles. Two of these cycles seem to be better ligands
for the imidazolate bridge to accommodate in: one is the 24-membered alicyclic hexaazamacrocycle/64/and
the other is the 24-membered octaazamacrocycle with three xyls/31/.
One of these metalloenzymes is Cu, Zn-SOD which is a dimeric protein (MW=31200) with two identical
subunits, each containing one Cu
+2 and one Zn+z ion. The direct utilization of this natural enzyme as a
pharmaceutical agent is limited because of low membrane permeability as a consequence of its high
molecular weight/66/. Therefore, considerable efforts were made in order to obtain nontoxic, low molecular
weight biomimetic molecules, which are able to catalyze the dismutation of superoxide anion and therefore to
provide a suitable alternative to superoxide dismutase in clinical application/17/. A variety of low molecular
weight complexes of transition metals, especially those of copper, were prepared and studied as SOD mimics
/64, 12/. Examples of such complexes include derivatives of the antiinflammatory drugs salicylates, amino
acids, peptides, and amines/12/.
Valproic acid (2-propylpentonoic acid) in the form of its sodium salt, (CH3CH2 CHz)2CHCOONa+, has a
wide spectrum of activity as an anticonvulsant drug/67/. The observation that copper (II) complexes of
anticonvulsant and antiinflammatory drugs are more active agents than the activity of such drugs may be due
to the in vivo formation of metallic complexes/68/. Physical studies of copper (II) valproate /69/ have shown
that it contains binuclear units with bridging carboxylate ligands similar to other copper (II) carboxylates
/70/. Several binuclear copper (II) carboxylates of antiinflammatory drugs such as salicylates /12/,
indomethacin/71/, and lonazoloc /72/ were studied as SOD mimics, but not of anticonvulsant drugs such as
valproate. In addition, it was reported that the presence of coordination sites belonging to nitrogen
heteroatomic rings such as imidazoles or pryridines is important for SOD activity/5/. And since complexes
with bipyridines and phenathrolines are DNA intercalators, showing an ability to inhibit nucleic acid
synthesis in vivo/73/, these ligands are used in this study to form ternary copper (II) valproate complexes.
Mn-SUPEROXIDE DISMUTASE
The Mn- and Fe-containing superoxide dismutases (SODs) are a family of enzymes which is widely
dispersed in microorganisms/74/. Two types of superoxide dismutases have been distinguished. The first
type includes those SODs for which the apoenzymes are active with only one of the metals: manganese or
iron, and replacement of that metal by the other results in loss of activity. For example, the E. Coli MnSOD is
active with manganese, but not with iron/75/, and FeSOD frown P. ovalis is active with iron only/76/. The
second type includes those SODs which are active with both metals. Such enzynes have been termed
"cambialistic SODs"/77/, an example being the SOD isolated by Matsumoto et al./78/, which was found to
be active either with nanganese or iron. Iron and manganese superoxide dismutases from bacterial sources
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have been shown by several crystallographic studies to be structural homologs. Their active sites of the iron
and manganese SODs share the same metal ligands, with silnilar ligand coordination geometries/74/. The
metal cofactor specificity of some enzymes is unclear in light of the structural similarities, but it is reasonable
to suppose, as it was suggested previously by others/74/, that the immediate environment of the metals in the
enzymes must differ.
The isolation of MnSOD from the Ba bacterium was reported /74/. This is a moderately halophilic
halotolerant microorganism which can withstand large variations in external salt concentrations. The enzyme
contains an inactive iron, which differs in its environment from the iron in E. coli FeSOD. The presence of
manganese and iron in SOD from Bal raises the question of their role in the enzyme’s activity. The fact that
H201, known to inactivate FeSODs/79, 80/, did not affect the activity of SOD from Bal does not contribute
to clarify their activity in the enzyme.
SUPEROXIDE DISMUTASE ACTIVITY
The superoxide disnutase-mimetic activity of the binary Cu2(valp)4 complex and their ternary complexes
with diimines was studied using the alkaline MezSO-NBT method /12, 80/. A unit superoxide dismutase
activity is the concentration of complex or enzyme which causes 50% inhibition of alkaline Me2SO-nediated
reduction of NBT; this concentration is expressed as IC50 for comparative purposes. The data for SOD
mimetic activity of the complexes under investigation are shown in Table 1/80/. In addition, to ascertain the
effectiveness of the present complexes as functional SOD mimics, a comparison was made/80/of the IC50
of several known Cu (II) complexes (Table 1), which were previously demonstrated as SOD mimics/12/, by
the NBT method under the same conditions. The data suggest that the activities of the present complexes are
higher than those of other copper (II) complexes. The mechanism believed to be operating in both Cu, Zn-
SOD and Cu (If) complexes involves the initial binding of superoxide to be axial Cu (If) site, with
subsequent redox cycling of the Cu (II) ion (Eq. 3 and 4)/64/.
Cu
+2 + 02 Cu
+ + 02 (3)
Cu+ + 02" + 2H+-- Cu
+2 + H202 (4)
Some factors were suggested which may discriminate among the dismutation features of the copper (II)
complexes in vitro, and these may include: First a fast exchange of molecules axially linked to the center and
a limited steric hindrance to the approach of the superoxide anion are considered essential requirements for
the successful binding of the 02 radical/80/. Second the flexibility of the copper (ll) arrangement, which
facilitates the interaction of the 02" radical, followed by the rapid electron transfer reaction which results in
reduction to copper (ll)-O2" species /32/. Third the favorable response of rt-electrons of the coordinated
ligands in stabilizing the Cu(tl)-O2" interaction/7/.
The control of the free radical flux derived from, oxygen is jeopardized in many circumstances in which
superoxide (SO) anion production is excessive. This overproduction of SO can overwhelm the body’s ability
to catalytically dismute superoxide and reduce or eliminate the radical burden. This deleterious oxygen-
derived free radical has been demonstrated to be a mediator of reperfusion diseases, such as those following
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Table 1
Superoxide dismutase-Mimetic Activity/80/
Compound
_Cu2(valp)4, )
(Cu(valp)2(2,2-bpy)) HEO, (2)
Cu(valp)E(phen), (3)...
_Cu(valp)a(dmph), (4)
(Cu(valp)E(-4,4"-bpy),, (5)
(CUE(valp)4(t-4,4"-bpy)) (6)
Cu(salicylate)2
Cu(as irinate)2(py.ridine)2
-Cu(glycylglyc.inate)(2,2 "bPY), 3H20
_Cu(glycylglycinate)(phen), 3H20
Cu(cimetidine)2(C104)2
Cu,Zn-SO
IC50"/lm
10.4
4.2
4.5
6.3
18.3
5.0
44
13
25
32
4.0
0.72
aI50 is defined as the concentration of complex or enzyme which produces 50%
inhibition ofNBT reduction.
acute myocardial infarct or stroke, and shown to be associated with development and continuation of
inflammatory processes, involved in diseases such as arthritis, and to play a major role in the initiation of
neurological disorders such as Parkinson’s disease/81/. Given the high reactivity of the superoxide radical,
however, it was hypothesized that Cu, Zn-SOD might also associate with the membrane surfaces of
mitochondria and peroxisomes, both of which generate substantial amounts of this radical. To test this
hypothesis the subcellular localization of Cu, Zn-SOD was examined in rat brain and liver as well as in
cultured human fibroblasts with the use of antibodies specific for Cu, Zn-SOD, Mn-SOD. This test provided
direct evidence that Cu, Zn-SOD is associated with both mitochondria and peroxisomes in the brain, liver,
and fibroblasts/82/. Higher organisms produce superoxide anion as an occasional byproduct during the one-
electron reduction of dioxygen; this occurs in respiration and photosynthesis. Also, in animals, macrophases
generate superoxide as part of the immune response. Organisms must therefore have ways to regulate
superoxide concentrations since excess amounts can inactivate enzymes containing iron-sulfur clusters and
can lead to the formation of highly oxidizing species damaging to other cellular constituents/83/. Recently,
the three-dimensional structure of Cu, Zn-SOD from photobacterium leiognathi has been reported and
interesting differences with respect to the eukaryotic SODs have been described concerning the dimer
interface region and the assembly of the electrostatic loop forming the active site/84/. This enzyme catalyses
a very rapid two-step dismutation of superoxide to dioxygen and hydrogen peroxide through an alternate
reduction and oxidation of the active-site copper ion/85/.
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CONCLUSION
Our vast knowledge of superoxide dismutase (SOD) chemistry and biology is moving the field towards
new and exciting directions. There are detailed issues relating to the mechanism and its biological functions
that are being addressed. It is important to note that these enzymes are involved in the biosynthesis of
metabolites, which form the largest pool of compounds from which numerous pharmaceutical substances
have been discovered. We can expect new and exciting developments in this area in the near future. Several
model studies have advanced our understanding of the interacting SOD in biological systems.
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